Mesoblast (MEOBF) Interest Expenses (2014 - 2023)
Mesoblast's (MEOBF) quarterly Interest Expenses came in at -$3.8 million in Q2 2023, up 4.58% year-over-year from -$3.6 million in Q2 2022, and up 24.28% quarter-over-quarter from -$5.0 million in Q1 2023.
Analysis
Mesoblast (MEOBF) Interest Expenses (2014 - 2023) Analysis & Trends
Mesoblast has disclosed Interest Expenses across 10 years of filings, most recently posting -$3.8 million for Q2 2023.
- In Q2 2023, Interest Expenses rose 4.58% year-over-year to -$3.8 million; the TTM figure through Jun 2023 stood at -$19.4 million (down 15.01% YoY), while the FY2026 annual figure was -$19.9 million, up 8.65% from the prior year.
- Interest Expenses came in at -$3.8 million for Q2 2023 at Mesoblast, up from -$5.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of -$1.1 million in Q4 2020 to a low of -$9.8 million in Q1 2020.
- Average Interest Expenses over 5 years is -$4.6 million, with a median of -$3.9 million recorded in 2022.
- Year-over-year, Interest Expenses plunged 554.37% in 2019 and soared 83.41% in 2020.
- Over 5 years, Interest Expenses stood at -$6.4 million in 2019, then soared by 83.41% to -$1.1 million in 2020, then slumped by 406.59% to -$5.4 million in 2021, then decreased by 15.02% to -$6.2 million in 2022, then jumped by 39.01% to -$3.8 million in 2023.
- Per Business Quant data, the three most recent Interest Expenses figures were -$3.8 million in Q2 2023, -$5.0 million in Q1 2023, and -$6.2 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.13 Bn | 9.29 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.23 Bn | 5.23 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.82 Bn | 3.52 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.68 Bn | 2.72 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.08 Bn | 3.08 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn | - |
| 9 | Vericel | 2.00 Bn | 1.84 Bn | 56.40 Mn | 160,000.00 |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -3.77 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -6.19 Mn |
| Sep 30, 2022 | -4.50 Mn |
| Jun 30, 2022 | -3.96 Mn |
| Mar 31, 2022 | -3.91 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -3.66 Mn |
| Jun 30, 2021 | -8.75 Mn |
| Mar 31, 2021 | -3.23 Mn |
| Dec 31, 2020 | -1.06 Mn |
| Sep 30, 2020 | -2.90 Mn |
| Mar 31, 2020 | -9.81 Mn |
| Dec 31, 2019 | -6.40 Mn |
| Sep 30, 2019 | -3.46 Mn |
| Jun 30, 2019 | -3.42 Mn |
| Mar 31, 2019 | -2.77 Mn |
| Dec 31, 2018 | -2.49 Mn |
| Sep 30, 2018 | -2.65 Mn |
| Jun 30, 2018 | -1.41 Mn |